Adaptimmune Therapeutics PLC - - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ADAP Nasdaq 8731 https://www.adaptimmune.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adaptimmune Therapeutics PLC -

Adaptimmune gets FDA designation to accelerate development of cancer therapy - Dec 3rd, 2019 7:20 pm
Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma - Dec 3rd, 2019 1:30 pm
Edited Transcript of ADAP earnings conference call or presentation 6-Nov-19 1:00pm GMT - Nov 17th, 2019 4:40 pm
Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma - Nov 16th, 2019 7:00 am
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update - Nov 6th, 2019 12:30 pm
Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019 - Nov 1st, 2019 12:00 pm
Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds - Oct 31st, 2019 5:52 pm
Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies - Oct 9th, 2019 12:00 pm
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer - Oct 1st, 2019 12:00 pm
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO - Sep 30th, 2019 12:45 pm
Does The Adaptimmune Therapeutics plc (NASDAQ:ADAP) Share Price Fall With The Market? - Sep 16th, 2019 10:41 am
Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy - Sep 10th, 2019 1:01 pm
United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4 - Sep 9th, 2019 12:00 pm
Edited Transcript of ADAP earnings conference call or presentation 1-Aug-19 12:00pm GMT - Aug 27th, 2019 6:11 pm
Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients - Aug 27th, 2019 12:00 pm
What's in Store for Aytu BioScience's (AYTU) Q4 Earnings? - Aug 16th, 2019 3:23 pm
Adaptimmune Therapeutics (ADAP) Q2 2019 Earnings Call Transcript - Aug 2nd, 2019 2:24 am
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update - Aug 1st, 2019 11:15 am
New Executive Team Announced at Adaptimmune - Aug 1st, 2019 11:15 am
Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019 - Jul 29th, 2019 8:05 pm